Gyre Therapeutics, INC 10-Q quarterly reports

Gyre Therapeutics, Inc. reported a net loss of $14.3 million for the second quarter of 2026, with revenues decreasing by 2% year-over-year, primarily due to a decline in collaboration revenue.

Gyre Therapeutics reports a significant increase in Q3 2025 revenue and net income, driven by successful new product launches and strong ETUARY sales.

Gyre Therapeutics reported a decrease in Q2 revenue and net income, but significantly bolstered its cash reserves through a public offering and advanced key pipeline assets.

Gyre Therapeutics reports a decrease in Q1 2025 revenue compared to Q1 2024, but highlights strategic initiatives including the acquisition of Nintedanib and progress in clinical trials.

Gyre Therapeutics reported a decrease in revenue for the third quarter of 2024, while highlighting strategic initiatives including new product acquisitions and clinical trial advancements.

Gyre Therapeutics reported a net income of $14.5 million for the first six months of 2024, despite a decrease in revenue compared to the same period last year, primarily due to normalized anti-fibrosis drug sales.

Gyre Therapeutics reported a net income of $9.9 million for the first quarter of 2024, driven by increased sales of its key product, ETUARY.